Changes in knowledge of cervical cancer following introduction of human papillomavirus vaccine among women at high risk for cervical cancer

L. Stewart Massad a,⁎, Charlesnika T. Evans b,c, Kathleen M. Weber d, Gypsyamber D'Souza e, Nancy A. Hessol f, Rodney L. Wright g, Christine Colie h, Howard D. Strickler i, Tracey E. Wilson j

a Department of Obstetrics & Gynecology, Washington University School of Medicine, St. Louis, MO, United States
b Department of Preventive Medicine and Center for Healthcare Studies, Northwestern University, Chicago, IL, United States
c Department of Veterans Affairs Hines Jr. VA Hospital, Hines, IL, United States
d The CORE Center at John H. Stroger Jr. Hospital of Cook County, Chicago, IL, United States
e Department of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States
f Departments of Clinical Pharmacy and Medicine, University of California, San Francisco, CA, United States
g Department of Obstetrics & Gynecology and Women's Health, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, United States
h Department of Obstetrics & Gynecology, Georgetown University School of Medicine, Washington, DC, United States
i Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, United States
j Department of Community Health Sciences, State University of New York, Downstate Medical Center, Brooklyn, NY, United States

ARTICLE INFO

Article history:
Received 19 December 2014
Accepted 28 February 2015
Available online 8 March 2015

Keywords:
Human papillomavirus
Cervical cancer prevention
Pap test
Health education
Human immunodeficiency virus in women

ABSTRACT

Purpose: To describe changes in knowledge of cervical cancer prevention, human papillomavirus (HPV), and HPV vaccination among women at high risk for cervical cancer in the first five years after introduction of HPV vaccination.

Methods: In 2007, 2008–9, and 2011, women in a multicenter U.S. cohort study completed 44-item self-report questionnaires assessing knowledge of cervical cancer prevention, HPV, and HPV vaccination. Results across time were assessed for individuals, and three study enrollment cohorts were compared. Knowledge scores were correlated with demographic variables, measures of education and attention, and medical factors. Associations were assessed in multivariable models.

Results: In all, 974 women completed three serial questionnaires; most were minority, low income, and current or former smokers. The group included 652 (67%) HIV infected and 322 (33%) uninfected. Summary knowledge scores (possible range 0–24) increased from 2007 (12.8, S.D. 5.8) to 2008–9 (13.9, S.D. 5.3, P < 0.001) and to 2011 (14.3, S.D. 5.2, P = 0.0001 vs 2007 and <0.04 vs 2008–9). Higher knowledge scores at first and follow-up administration of questionnaires, higher income, and higher education level were associated with improved knowledge score at third administration. Women not previously surveyed had scores similar to those of the longitudinal group at baseline.

Conclusion: Substantial gaps in understanding of HPV and cervical cancer prevention exist despite years of health education. While more effective educational interventions may help, optimal cancer prevention may require opt-out vaccination programs that do not require nuanced understanding.

© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Indigent and minority women and those with multiple sexual partners are at particular risk for cervical cancer. These are also risk factors for infection with the human immunodeficiency virus (HIV), making HIV seropositivity a useful marker for cervical cancer risk. HIV increases HPV infections, abnormal Paps, and cervical cancer (Massad et al., 2008). Screening and precursor treatment reduce cancer risk even for women with HIV (Massad et al., 2009). However, cervical cancer prevention is complex, involving HPV vaccination, screenings, triage with HPV tests and colposcopy, and therapy. High risk women including those with HIV are often noncompliant (Cejtin et al., 1999). Understanding what women with HIV know about cervical cancer prevention may offer insights into how educational efforts might target high risk women.

Previous research involving a national cohort of women with HIV and comparison HIV-uninfected women demonstrated knowledge gaps related to risk factors for and consequences of HPV infection. These women also have limited understanding of cervical cancer prevention methods (Massad et al., 2010a, 2010b). Knowledge correlated

http://dx.doi.org/10.1016/j.gore.2015.02.007
2352-5789/© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
with HIV seropositivity, white ethnicity, higher income, more education, better reading skills, and prior abnormal Pap (Massad et al., 2010a). Knowledge had little impact on colposcopy compliance (Massad et al., 2012), perhaps because knowledge remained suboptimal despite improving after an educational intervention (Massad et al., 2010b).

Since vaccine introduction in 2006, marketing and media coverage have exposed many U.S. women to information about cervical cancer, HPV, and HPV vaccination (Kelly et al., 2009; Gottlieb, 2013), but the impact of these messages on high risk women is unclear. This analysis extends prior research by exploring trends over time in knowledge and attitudes. In addition, we assessed knowledge in a cohort of women without prior experience with our questionnaire enrolled after HPV vaccine release.

**Results**

Of 1451 women completing questionnaires in 2007, 974 (67%) completed three serial questionnaires. Of these, 652 (67%) were completed by HIV seropositive and 322 (33%) by seronegative women. Risk factors by HIV seropositive and 322 (33%) by seronegative women. Risk factors for cervical cancer including minority ethnicity, low annual income, and current or former smoking history were present in the majority of participants (Table 1). When compared to HIV seronegative women, HIV seropositive women were older, more likely to be non-Hispanic white, and less likely to currently use alcohol, tobacco, or drugs.

Individual component results of questionnaires across the three recruitment waves are presented in Tables 1–3. Supplemental digital content. Mean knowledge scores increased across administrations, from 12.8 (S.D. 5.8) at baseline to 13.9 (S.5.3) at follow-up (P < 0.0001) to 14.3 (S.D. 5.2) at third administration (P < 0.0001 vs baseline and <0.04 vs follow-up). As scores are out of a possible 24, even improved later scores reflect limited knowledge. Lower baseline scores of HIV seronegative women (11.7 with S.D. 6.0) versus HIV seropositive women (13.3 S.D. 5.7, P < 0.0001) were eliminated by the third questionnaire administration (13.9 with S.D. 5.3 among HIV uninfected vs 14.4 with S.D. 5.1 among HIV infected women, P = 0.12). No improvement in knowledge of HPV vaccine, its indications, or its target population was observed between the follow-up and third questionnaire administrations. Although small increases in knowledge were seen, at the third questionnaire administration only 56% of all women studied knew that Pap testing checked the cervix, 46% knew it should be repeated at 1–3 year intervals for women with HIV. In contrast, 83% of all women studied knew that annual Pap testing was indicated for women with

| Table 1 |
|---|
| **Baseline demographic and medical characteristics of women who completed questionnaires at three consecutive surveys (n = 974), n (%).** |
| | HIV+ N = 652 | HIV− N = 322 | P-value* |
| --- | --- | --- | --- |
| **Age at baseline interview (years)** | | | 0.0001 |
| <30 | 5 (0.8) | 30 (9.3) | |
| 30–39 | 116 (17.8) | 85 (26.4) | |
| 40–49 | 268 (41.1) | 116 (34.2) | |
| 50+ | 263 (40.3) | 97 (30.1) | |
| **Ethnicity** | | | |
| Non-Hispanic African American | 418 (64.1) | 205 (63.6) | 0.0054 |
| Hispanic | 115 (17.7) | 78 (24.2) | |
| Non-Hispanic White | 94 (14.4) | 25 (7.8) | |
| Other | 25 (3.8) | 14 (4.4) | |
| **Average annual household income (n = 941)** | | | 0.0011 |
| <=$5000 | 78 (12.3) | 59 (19.3) | |
| $6001–$12,000 | 224 (35.3) | 77 (25.2) | |
| $12,001–$18,000 | 69 (10.8) | 45 (14.7) | |
| $18,001+ | 264 (41.6) | 125 (40.8) | |
| **Education level (n = 973)** | | | 0.3743 |
| Less than high school | 213 (32.7) | 109 (34.0) | |
| Completed high school | 201 (30.8) | 109 (34.0) | |
| Some college/college degree | 238 (36.5) | 103 (32.0) | |
| **Site/location** | | | |
| Bronx | 101 (15.5) | 60 (18.6) | 0.0017 |
| Brooklyn | 201 (30.8) | 69 (21.4) | |
| Washington DC | 97 (14.9) | 44 (13.7) | |
| Los Angeles | 72 (11.0) | 58 (18.0) | |
| San Francisco | 87 (13.4) | 54 (16.8) | |
| Chicago | 94 (14.4) | 37 (11.5) | |
| **Alcohol use** | | | |
| Abstainer | 371 (56.9) | 133 (41.3) | <0.0001 |
| Light (<3 drinks/week) | 200 (30.7) | 111 (34.5) | |
| Moderate/heavy (3+ drinks/week) | 81 (12.4) | 78 (24.2) | |
| **Current smoker** | | | 0.0197 |
| Current user | 235 (36.0) | 143 (44.4) | |
| Former user | 226 (34.7) | 107 (32.2) | |
| Never | 191 (29.3) | 72 (22.4) | |
| **Injection drug use status** | | | 0.0361 |
| Current user | 4 (0.6) | 8 (2.5) | |
| Former user | 42 (6.5) | 24 (7.5) | |
| Never | 606 (92.9) | 290 (90.0) | |
| **Non-injection drug use status** | | | <0.0001 |
| Current user | 119 (18.3) | 94 (29.2) | |
| Former user | 242 (37.1) | 132 (41.0) | |
| Never | 291 (44.6) | 96 (29.8) | |
| **Lifetime nadir CD4 lymphocyte count (cells/mm$^3$) (n = 626)** | | | |
| <200 | 200 (32.0) | 149 (46.3) | |
| 200–500 | 149 (23.7) | 74 (22.8) | |
| >500 | 77 (12.3) | 10 (3.1) | |
| **CD4 lymphocyte count (cells/mm$^3$) at visit (n = 642)** | | | |
| <200 | 75 (11.7) | 3 (0.8) | |
| 200–500 | 197 (30.7) | 14 (4.4) | |
| >500 | 370 (57.6) | 30 (9.3) | |

* By chi-square test.
HIV and prior negative screening, 79% knew that Pap testing checks for precancer and cancer, 74% knew that HPV is a sexually transmitted virus that causes genital warts and cancers, and 78% knew that women with HPV are at higher risk for cancer. These results were minimally changed from the follow-up administration of the questionnaire.

Independent factors associated with an improvement in knowledge score at the third, previously unreported administration of the survey included higher knowledge scores at first and follow-up administration of questionnaires, higher income, and higher education level (Table 2). There was also a significant difference in knowledge score by site. R-squared for this model was 0.35, indicating that these factors explained approximately one third of the magnitude of change. HIV status was not significant after controlling for these factors, nor was drug use.

A cross-sectional analysis of the third administration of the survey evaluated knowledge among women in a recently enrolled cohort. The survey was completed by 1968 women (979 cohort 1, 734 cohort 2, 255 cohort 3). Overall there was a higher percentage of HIV seropositive women in the third compared to the first and second cohorts (82.5% vs 74.6% and 63.5%, P < 0.0001). The average age in the first, second and third cohorts respectively were 51.4, 41.1, and 44.1 years. In addition, compared to the first and second cohorts, the third cohort was more likely to be non-Hispanic African-American, to have lower income, to report alcohol or drug use, and to be a current smoker. There also were differences in CD4 counts below 200 cells/mm³: cohort 1, 63.4%, cohort 2, 22.3%, cohort 3, 30.5, P < 0.0001. Although mean scores did not differ between first and second enrollment cohorts (14.0 (S.D. 5.2) vs 13.8 (5.4), P = 0.27), scores were lower for the third (12.5 (5.8), P = 0.0001 vs the first cohort and P = 0.002 vs the second cohort). Specific differences among cohorts are presented in Tables 1–3 of Supplemental digital content, but differences were present across all components of the questionnaire. Only 50–60% of women in all cohorts believed cervical cancer is preventable. Only about 60% of women in the first and second cohorts said that they had heard of the HPV vaccine (Table 3, Supplemental digital content), although all had been informed during previous iterations of the questionnaire: only 43% of women in the third cohort said that they had heard of the HPV vaccine (P < 0.0001). Despite this, some three fourths of all cohorts knew that the HPV vaccine was targeted to adolescents and teens. Furthermore, 71% of both the first and second enrollment cohorts knew that the vaccine prevented abnormal Pap tests and cervical precancer and cancer, though only 62% of women in the third cohort knew this (P = 0.01). A multivariable model demonstrated that being in the first or second recruitment cohort wave was associated with a higher knowledge score compared to those recruited in the last wave. In addition, being HIV positive or a former or current drug user, younger age, having a higher income or education level, and being a white non-Hispanic respondent was associated with higher knowledge scores (Table 2).

**Discussion**

Cervical cancer disproportionately affects poor and minority U.S. women, largely because they fail to receive screening. HPV vaccination lowers risk, but the U.S. vaccination program requires parents to elect vaccination for their children, which in turn requires understanding of risks and indications.

Among women at high cervical cancer risk, knowledge of cervical cancer prevention has improved, but gaps remain. Women newly enrolled into our cohort had knowledge scores lower than those of previously enrolled women but similar to baseline scores in prior cohorts, as previous administrations of the questions and an educational intervention involving provision of their answers improved knowledge (Massad et al., 2010b). Nevertheless, appreciation of cervical cancer prevention processes among similar women outside the study is likely to be less than optimal to support informed screening compliance and election of HPV vaccination for themselves and their children.

Our results are similar to others’, though our study includes longitudinal results. Kelly and colleagues showed that despite a sharp increase in knowledge of the link between HPV and cervical cancer after vaccine introduction, knowledge leveled off below 60% (Kelly et al., 2009). Joseph and associates found that only half of low-income women surveyed in 2007–2012 knew that HPV causes cervical cancer and that knowledge deficits were greater among minority women (Joseph et al., 2014). Strohl et al. found low knowledge scores among Chicago African American women (Strohl et al., 2014).

**Table 2**

Analysis of Covariance Models assessing factors associated with cervical cancer prevention knowledge score at third survey administration among high risk women. Both models controlled for study site.

| Predictor variables                      | Model for women completing all 3 survey administrations N = 974 | Model for women who completed the third survey administration N = 1968 |
|-----------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| Adjusted R²                             | 0.35                                                          | 0.10                                                          |
| F-value                                 | 46.96***                                                      | 18.2***                                                      |
| Intercept                               | 8.94 (7.47, 10.46)***                                         | 15.69 (14.60, 16.79)***                                       |
| Total baseline score (1st)              | 0.27 (0.22, 0.33)***                                          |AYS (0.22, 0.34)***                                           |
| Total follow-up score (2nd)             | 0.28 (0.22, 0.34)***                                          |AYS (0.22, 0.34)***                                           |
| Recruitment cohort (vs 3rd cohort)      |                                                               |AYS (0.22, 0.34)***                                           |
| Cohort 1                                |                                                               |AYS (0.22, 0.34)***                                           |
| Cohort 2                                | 1.12 (0.36, 1.88)***                                          |AYS (0.20, 1.71)***                                           |
| HIV seropositive (vs negative)          | −0.18 (−0.75, 0.39)                                          |AYS (−0.003, 1.03)***                                         |
| Age less than 50 (vs 50+ years)         | 0.52 (−0.003, 1.03)                                          |AYS (0.17, 1.24)***                                           |
| Ethnicity (vs White NH)                 | −1.76 (−2.52, −1.00)***                                       |AYS (−1.95, 0.27)***                                          |
| Non-Hispanic African American           | −1.50 (−2.36, −0.64)***                                       |AYS (−1.95, 0.27)***                                          |
| Hispanic                                | −1.61 (−2.95, −0.27)***                                       |AYS (−1.95, 0.27)***                                          |
| Other                                   |                                                               |AYS (−1.95, 0.27)***                                          |
| Education (vs College)                  |                                                               |AYS (−1.95, 0.27)***                                          |
| Less than high school                   | −0.88 (−1.57, −0.18)*                                         |AYS (−2.61, −2.20)***                                         |
| Completed high school                   | −0.10 (−0.76, 0.57)                                          |AYS (−0.96, −0.37)***                                         |
| Income < $18,000 (vs > $18,000)         | −0.82 (−1.41, −0.24)**                                        |AYS (−1.27, −0.75)***                                         |
| Drug use (vs never)                     |                                                               |AYS (−1.27, −0.75)***                                         |
| Former user                             | 0.85 (0.30, 1.39)***                                          |AYS (0.61 (−0.01, 1.22)***|
| Current user                            |                                                               |AYS (0.61 (−0.01, 1.22)***|

* p < 0.05.
** p < 0.1.
*** p < 0.001.
U.S. HPV vaccination rates are suboptimal, and African-American adolescents and young uninsured women are less likely to be vaccinated (Pierce Campbell et al., 2012). Inadequate appreciation of vaccine benefits and risks pose a barrier to vaccination (Donadiki et al., 2014). Messages targeted to poor and minority women are needed to improve vaccination rates, and our results suggest that these messages may have to clarify very basic concepts.

Inclusion of women with HIV was a strength of the study. Such women are at particular risk, in part because of immunosuppression but also because they have multiple cancer risk factors such as smoking and multiple sexual partners. Other strengths include serial survey administration and the multisite cohort.

This study was limited by several factors. Women were participating in semiannual Pap screening as part of the WIHS, so we could not assess impact of knowledge on screening or vaccination. Screening guidelines changed after the 2011 administration of our questionnaire, and current understanding about screening intervals and tests might not reflect these new recommendations. Most study women were older than the target age for HPV vaccination, and we did not assess the impact of knowledge or attitudes on vaccination rates among young relatives who might be vaccination candidates. We could not determine whether differences between prior and most recent enrollees were due to longer experience with cervical cancer prevention in WIHS, familiarity with questionnaires, or other factors distinguishing enrollment cohorts. However, our finding that knowledge of cervical cancer prevention was lower among newest recruits indicates that passive learning from media, family and friends, and health care providers in recent years is insufficient. Finally, women enrolled in WIHS may be selected. However, women outside frequent care and women who have not dedicated themselves to a decade-long study are likely to be even less informed about cervical cancer prevention than participants in our study.

Not all items assessed in our question set may directly influence prevention and treatment behaviors. For instance, while women should be aware of guidelines on Pap frequency, knowing diet does not impact cervical cancer risk may be less important. Further research to better define determinants of HPV prevention and cervical cancer detection/treatment behaviors and to identify subgroups at greater risk based on these determinants may aid in designing and disseminating more effective strategies to improve these outcomes.

Misperceptions about cervical cancer prevention remain common among the largely poor and minority women in our study. While specific educational efforts may improve understanding and prevention behavior, school based or mandatory HPV vaccination may have greater long-term impact. Opt-out approaches may yield better vaccination rates than opt-in approaches that require weighing of vaccine benefits and risks. Long-term progress against cervical cancer may require additional messages on providing women at high risk for cervical cancer with the understanding they need to enroll their children in routine HPV vaccination programs.

Compliance with ethical standards

The authors report no potential conflicts of interest. Funding is outlined in the Acknowledgement. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Specifically, informed consent was obtained from all individual participants included in the study, and the WIHS was approved by the local and national institutional review boards.

Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.gore.2015.02.007.

Acknowledgement

Data in this manuscript were collected by the Women's Interagency HIV Study (WIHS). The contents of this publication are solely the responsibility of the authors and do not represent the official views of the National Institutes of Health (NIH). WIHS (Principal Investigators): Bronx WIHS (Kathryn Anastos), U01-AI-035004; Brooklyn WIHS (Howard Minkoff and Deborah Gustafson), U01-AI-031834; Chicago WIHS (Mardge Cohen), U01-AI-034993; Metropolitan Washington WIHS (Mary Young), U01-AI-034994; Connie Wofsy Women's HIV Study, Northern California (Ruth Greenblatt, Bradley Aouizerat, and Phyllis Tien), U01-AI-034989; WIHS Data Management and Analysis Center (Stephen Gange and Elizabeth Golub), U01-AI-042590; Southern California WIHS (Joel Milam), U01-HD-032632 (WIHS I–WIHS IV). The WIHS is funded primarily by the National Institute of Allergy and Infectious Diseases (NIAID), with additional co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Cancer Institute (NCI), the National Institute on Drug Abuse (NIDA), and the National Institute on Mental Health (NIMH). Targeted supplemental funding for specific projects is also provided by the National Institute of Dental and Craniofacial Research (NIDCR), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute on Deafness and other Communication Disorders (NIDCD), and the NIH Office of Research on Women's Health. WIHS data collection is also supported by UL1-TR000004 (UCSF CTSA).

References

Bacon, M., von Wyl, V., Alden, C., Sharp, G., Robison, E., Hessol, N., et al., 2005. The Women's Interagency HIV Study: an observational cohort bringing clinical science to the bench. Clin. Diagn. Lab. Immunol. 12, 1013.

Barkan, S.E., Melnick, S.L., Martin-Preston, S., Weber, K., Kalish, L.A., Miotto, P., et al., 1998. The Women’s Interagency HIV Study. Epidemiology 9, 117–125.

Cejtin, H., Romanoff, E., Massad, L.S., Korn, A., Schmidt, J.B., Eisenberger-Matthyuba, D., et al., 1999. Adherence to colposcopy among women with HIV infection. J. Acquir. Immune Defic. Syndr. Hum. Retrovirology 22, 247–252.

Donadiki, E.M., Jiménez-García, R., Hernández-Barrera, V., Sourtzi, P., Carasco-Garrido, P., López de Andrés, A., et al., 2014. Health Belief Model applied to non-compliance with HPV vaccine among female university students. Public Health 128 (3), 268–273 (Mar).

Gottlieb, S.D., 2013. The patient–consumer–advocate nexus: the marketing and dissemination of Gardasil, the human papillomavirus vaccine, in the United States. Med. Anthropol. Q. 27, 330–347.

Joseph, N.P., Clark, J.A., Mercilus, G., Wilbur, M., Figaro, J., Perkins, R., 2014. Racial and ethnic differences in HPV knowledge, attitudes and vaccination rates among low-income African-American, Haitian, Latina, and Caucasian young adult women. J. Pediatr. Adolesc. Gynecol. 27, 83–92.

Kelly, B.J., Leader, A.E., Mittermaier, D.I., Hornik, R.C., Cappella, J.N., 2009. The HPV vaccine and the media: how has the topic been covered and what are the effects on knowledge about the virus and cervical cancer? Patient Educ. Couns. 77, 308–313.

Massad, L.S., Seaberg, E.C., Wright, R.L., Darragh, T., Lee, Y.C., Colie, C., et al., 2008. Squamous cervical lesions in women with Human Immunodeficiency Virus: long-term follow up. Obstet. Gynecol. 111, 1388–1393.

Massad, L.S., Seaberg, E.C., Watts, D.H., Minkoff, H., Levine, A.M., Henry, D., et al., 2009. Long-term incidence of cervical cancer in women with HIV. Cancer 115, 524–530.

Massad, L.S., Evans, C.T., Wilson, T.E., Goderre, J.L., Hessol, N.A., Henry, D., et al., 2010a. Knowledge of cervical cancer prevention and human papillomavirus among women with HIV. Gynecol. Oncol. 117, 70–76.

Massad, L.S., Evans, C.T., Weber, K.M., Goderre, J.L., Hessol, N.A., Henry, D., et al., 2010b. Changes in knowledge of cervical cancer prevention and human papillomavirus among women with HIV, 2006–2008. Obstet. Gynecol. 116, 941–947.

Massad, L.S., Wilson, T.E., Goderre, J.L., Hessol, N.A., Henry, D., Colie, C., et al., 2012. Correlating knowledge of cervical cancer prevention and human papillomavirus with compliance after colposcopy referral. J. Low. Genit. Tract Dis. 16, 89–105.

Pierce Campbell, C.M., Menezes, L.J., Paskett, E.D., Giuliano, A.R., 2012. Inequalities in the uptake of human papillomavirus vaccination: a systematic review and meta-analysis. Cancer Epidemiol. Biomarkers Prev. 21, 1402–1408.

Stroh, A.E., Mendoza, G., Ghant, M.S., Cameron, K.A., Simon, M.A., et al., 2014. Barriers to prevention: knowledge of HPV, cervical cancer, and HPV vaccinations among African American women. Am. J. Obstet. Gynecol. http://dx.doi.org/10.1016/j.ajog.2014.06.093 (2014 Jun 28. pii: S0002-9378(14)00639-5).